Moran M J, Fontanellas A, Brudieux E, Hombrados I, de Ledinghen V, Couzigou P, de Verneuil H, De Salamanca R E
Laboratoire de Pathologie Moléculaire et Thérapie Génique, Université de Bordeaux II, France.
Hepatology. 1998 Feb;27(2):584-9. doi: 10.1002/hep.510270237.
Porphyria cutanea tarda (PCT) is caused by a decreased activity of the hepatic enzyme uroporphyrinogen decarboxylase (URO-D). This deficiency causes overproduction, hepatic deposition, and increased excretion of uroporphyrin. Iron overload and hepatic viral infections are considered aggravating factors of the disease. Two forms of PCT have been described, as follows: a familial one with an inherited decrease of URO-D activity in all tissues and a sporadic one with a decreased activity of URO-D restricted to the liver. To assess whether the hepatic URO-D returns to normal during a remission of the disease, this activity was measured in liver biopsy samples in 24 sporadic PCT patients. The hepatic and urinary porphyrin concentrations were also measured. Viral status and histopathological findings were analyzed to assess their involvement in PCT. Six patients treated by phlebotomy to reduce hepatic iron and who were considered to be in clinical remission, characterized by a disappearance of cutaneous lesions, showed higher hepatic URO-D activities and lower hepatic porphyrin concentrations than did patients with overt PCT. The medians of these variables, however, did not achieve normal values. The hepatic URO-D activity showed a significant inverse relationship with both hepatic porphyrins and urinary uroporphyrin excretion. Hepatic URO-D activity was not reduced by hepatitis C virus (HCV) infection and liver damage. We conclude that the achievement of remission in PCT largely depends on the transient normalization of hepatic URO-D activity. A small increase in hepatic coproporphyrin in nonporphyric patients could reflect hepatic injury/iron/alcohol-induced oxidative stress oxidizing the accumulated heme precursors rather than a direct effect on hepatic URO-D enzyme.
迟发性皮肤卟啉症(PCT)是由肝脏酶尿卟啉原脱羧酶(URO-D)活性降低引起的。这种缺陷导致尿卟啉产生过多、肝脏沉积以及排泄增加。铁过载和肝脏病毒感染被认为是该疾病的加重因素。已描述了两种形式的PCT,如下:一种是家族性的,所有组织中URO-D活性遗传性降低;另一种是散发性的,URO-D活性降低仅限于肝脏。为了评估疾病缓解期间肝脏URO-D是否恢复正常,对24例散发性PCT患者的肝活检样本进行了该活性测定。还测量了肝脏和尿液中的卟啉浓度。分析病毒状态和组织病理学结果以评估它们在PCT中的作用。6例通过放血以减少肝脏铁含量且被认为处于临床缓解期(以皮肤病变消失为特征)的患者,其肝脏URO-D活性高于明显PCT患者,肝脏卟啉浓度低于明显PCT患者。然而,这些变量的中位数未达到正常值。肝脏URO-D活性与肝脏卟啉和尿液尿卟啉排泄均呈显著负相关。丙型肝炎病毒(HCV)感染和肝损伤并未降低肝脏URO-D活性。我们得出结论,PCT缓解的实现很大程度上取决于肝脏URO-D活性的短暂正常化。非卟啉症患者肝脏粪卟啉的小幅增加可能反映肝脏损伤/铁/酒精诱导的氧化应激使积累的血红素前体氧化,而不是对肝脏URO-D酶的直接作用。